Skip to main content
. 2022 Mar 15;12:4398. doi: 10.1038/s41598-022-08449-w

Figure 2.

Figure 2

Subgroup analysis of OS of EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups.